文献速递艾滋病与性传播感染

多拉韦林联合拉米夫定两药方案作为HIV感染者维持抗逆转录病毒治疗:一项法国观察性研究

Doravirine plus lamivudine two-drug regimen as maintenance antiretroviral therapy in people living with HIV: a French observational study.
PubMed 文献 · J Antimicrob Chemother · 2023-01-01

这项法国观察性研究纳入50例已长期病毒抑制的HIV感染者,换用多拉韦林/拉米夫定维持治疗,第48周病毒学成功率为98.0%(95%CI 89.4-99.9),随访期间CD4/CD8比值无显著变化而CD4 T细胞计数显著升高。作者认为该两药方案可在高度治疗经历且长期病毒抑制的感染者中维持高水平病毒抑制。

要点

  • 50例已病毒抑制的HIV感染者换用多拉韦林/拉米夫定,第48周病毒学成功率为98.0%(95%CI 89.4-99.9)。
  • 随访中发生1例病毒学失败(第18周HIV-RNA=101 copies/mL),基线无耐药且未出现耐药。
  • 3例因不良事件停用策略(消化系统紊乱2例、失眠1例),CD4/CD8比值无显著变化而CD4 T细胞计数显著升高。

核心结论

  • 这些初步发现提示,多拉韦林/拉米夫定方案可在高度抗逆转录病毒治疗经历且长期病毒抑制、CD4+ T细胞计数良好的HIV感染者中维持高水平病毒抑制。

研究设计与样本

  • 观察性研究,纳入2019年9月1日至2021年10月31日期间在参与Dat'AIDS队列的法国HIV中心启动多拉韦林/拉米夫定的全部成人,共50例。

主要发现

  • 50例中男性34例(68%),中位年龄58岁(IQR 51-62),抗逆转录病毒治疗时长20年(13-23),病毒学抑制时长14年(8-19),CD4计数784 cells/mm3(636-889)。
  • 换药前所有患者血浆HIV-RNA<50 copies/mL;除3例外均未使用过多拉韦林,36例(72%)来自三药方案。
  • 中位随访79周(IQR 60-96),第48周病毒学成功率98.0%(95%CI 89.4-99.9)。
  • 第18周发生1例病毒学失败(HIV-RNA=101 copies/mL),该患者因强烈噩梦短暂停用多拉韦林/拉米夫定;基线无耐药且未出现耐药。
  • 3例因不良事件停用策略(消化系统紊乱2例、失眠1例);CD4/CD8比值无显著变化,CD4 T细胞计数显著升高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Two-drug regimens based on integrase strand transfer inhibitors (INSTIs) and boosted PIs have entered recommended ART. However, INSTIs and boosted PIs may not be suitable for all patients. We aimed to report our experience with doravirine/lamivudine as maintenance therapy in people living with HIV (PLWH) followed in French HIV settings. METHODS: This observational study enrolled all adults who initiated doravirine/lamivudine between 1 September 2019 and 31 October 2021, in French HIV centres participating in the Dat'AIDS cohort. The primary outcome was the rate of virological success (plasma HIV-RNA < 50 copies/mL) at Week (W)48. Secondary outcomes included: rate of treatment discontinuation for non-virological reasons, evolution of CD4 count and CD4/CD8 ratio over follow-up. RESULTS: Fifty patients were included, with 34 (68%) men; median age: 58 years (IQR 51-62), ART duration: 20 years (13-23), duration of virological suppression: 14 years (8-19), CD4 count: 784 cells/mm3 (636-889). Prior to switching, all had plasma HIV-RNA < 50 copies/mL. All but three were naive to doravirine, and 36 (72%) came from a three-drug regimen. Median follow-up was 79 weeks (IQR 60-96). Virological success rate at W48 was 98.0% (95% CI 89.4-99.9). One virological failure occurred at W18 (HIV-RNA = 101 copies/mL) in a patient who briefly discontinued doravirine/lamivudine due to intense nightmares; there was no resistance at baseline and no resistance emergence. There were three strategy discontinuations for adverse events (digestive disorders: n = 2; insomnia: n = 1). There was no significant change in CD4/CD8 ratio, while CD4 T cell count significantly increased. CONCLUSIONS: These preliminary findings suggest that doravirine/lamivudine regimens can maintain high levels of viral suppression in highly ART-experienced PLWH with long-term viral suppression, and good CD4+ T cell count.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Perfezou P, Hall N, Duthe JC, et al. Doravirine plus lamivudine two-drug regimen as maintenance antiretroviral therapy in people living with HIV: a French observational study. J Antimicrob Chemother. 2023. PMID: 37303236. doi:10.1093/jac/dkad185

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。